Drug trial seeks to halt DR Congo’s deadliest Ebola outbreak

Clinical trials are seeking to stop the rare Bundibugyo strain (AP)

More than 250 participants have been enrolled in a trial for a drug that could stop them from contracting Ebola in the Democratic Republic of the Congo, in what experts have described as a critical step in the fight against the deadliest outbreak of the disease in the Central African country.

The drug is targeted at the Bundibugyo virus, which is responsible for the fast-moving outbreak and is currently without an approved vaccine or treatment.

The trial began in July and is one of several studies launched to find some protection and another way of at least slowing the outbreak.

The trial is taking place at a health centre in the eastern province of Ituri, the epicentre of the outbreak. The participants include people who have been exposed to the disease in this outbreak, among them health workers and patients’ relatives.

At least 8,300 confirmed cases, including 4,000 deaths, have been recorded since this Ebola outbreak was declared in mid-May in eastern DR Congo.

It has spread to seven provinces and continues to outpace efforts to track and slow it, authorities say.

The trial is testing Gilead’s experimental antiviral pill, called obeldesivir, which is given soon after suspected contact with the virus to prevent the disease from developing. That approach is called post-exposure prophylaxis, or PEP.

One participant in the trial known as EBO-PEP said she enrolled in the study in August after her husband tested positive for Ebola. She says so far no-one from her family has developed symptoms.

She and other trial participants requested anonymity to protect their privacy due to the sensitive nature of the Ebola outbreak and the medical protocol involved.

“I realised that if I even touched my husband — and I did touch him, his vomit, everything — (it meant that) I was a direct contact. I could have also passed on this contagious disease. I could have been contaminated,” the participant said.

She said she knew of entire households which had become infected after a family member tested positive for Ebola. But so far no-one from her family has developed symptoms, she says.

Ebola disease only spreads once symptoms begin. People exposed to infected patients have to wait to see if they become ill. Finding people at high risk of incubating the Bundibugyo virus – also known as contact tracing – has proved difficult in DR Congo.

Another participant said two of their family members had caught Ebola, and one of them had died. “This disease is killing. It’s better to take precautions,” he said.

The trial, coordinated by Alima, a medical non-profit body, aims to recruit nearly 1,000 adults or children over the age of 12 who have come into contact with a confirmed case within the last five days but have no symptoms. Half will get a placebo.

Participants are monitored in person every day for 21 days, with a final phone call after 42 days, according to Dr Godefroid Basara, who is working on the trial.

Alima said that if trial participants begin to develop symptoms, they will immediately receive supportive treatment, which has been shown to be helpful when symptoms are caught early.

If the pill proves effective, it could help break the infection chain.

“It differs from a vaccine, which may take days or weeks to provide protection. It is also different from curative treatment because it is intended for people who are not yet showing symptoms,” Alima research coordinator Dr Guilavogui Jean Paul Yassa said.

Dr Jacques Zawadi, an investigating physician working with ALIMA at the trial centre, said most participants are happy to take part in the study, but it had been challenging to encourage some people who live far from the centre to sign up.

He said the study is sometimes disrupted when participants find out their family members have died from the disease.

“This is the biggest challenge we face. When a person is emotionally affected, it is not easy to reason with them and ensure they return to the study,” he said.

The trial partners also include Congo’s National Institute of Biomedical Research and the French institute ANRS Emerging Infectious Diseases.